Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 22, 2026, 3:18 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Endothelial Physiopathology Clear all
Completed Phase 1Phase 2 Interventional Results available

Subarachnoid Hemorrhage and Soluble Epoxide Hydrolase Inhibition Trial

NCT03318783
View directory record Official record
Conditions
Subarachnoid Hemorrhage, Aneurysmal, Delayed Cerebral Ischemia, Vasospasm, Cerebral, Endothelial Dysfunction
Interventions
GSK2256294, Placebo
Drug
Lead sponsor
Oregon Health and Science University
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jan 21, 2021 · Synced Jul 22, 2026, 3:18 AM EDT
Completed Phase 4 Interventional Results available

Phosphate Lowering in CKD Trial

NCT02209636
View directory record Official record
Conditions
Chronic Kidney Disease, Cardiovascular Disease
Interventions
Lanthanum carbonate, placebo, Ascorbic Acid, Nitroglycerin, Flow-mediated dilation measurement, Aortic pulse-wave velocity, Endothelial cell collection
Drug · Procedure
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
40 Years to 79 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2019
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 25, 2022 · Synced Jul 22, 2026, 3:18 AM EDT
Completed Phase 4 Interventional Results available

Effect of Saxagliptin on EPCs as a Cellular Biomarker for Evaluating Endothelial Dysfunction in Early T2DM Patients

NCT02024477
View directory record Official record
Conditions
Type 2 Diabetes
Interventions
Saxagliptin, Placebo
Drug
Lead sponsor
George Washington University
Other
Eligibility
40 Years to 70 Years
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Feb 14, 2019 · Synced Jul 22, 2026, 3:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Airborne Ultrafine and Fine Particulate Matter: A Cause for Endothelial Dysfunction in Man?

NCT00814281
View directory record Official record
Conditions
Airway Inflammation
Interventions
placebo, Montelukast
Other · Drug
Lead sponsor
Marywood University
Other
Eligibility
18 Years to 30 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2009
U.S. locations
1
States / cities
Scranton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated May 20, 2009 · Synced Jul 22, 2026, 3:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

The Impact of Goode Health Beverage on Markers of Physiological and Neurocognitive Health

NCT06245382
View directory record Official record
Conditions
Cardiovascular Diseases, Hypertension, Cognitive Decline, Diet, Healthy
Interventions
Goode Health Beverage, Vanilla Base Beverage Blend
Dietary Supplement
Lead sponsor
The University of Texas at Arlington
Other
Eligibility
18 Years to 55 Years
Enrollment
22 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Arlington, Texas
Source: ClinicalTrials.gov public record
Updated Mar 31, 2025 · Synced Jul 22, 2026, 3:18 AM EDT
Completed Phase 2 Interventional Results available

Endothelial Facilitation in Alzheimer's Disease

NCT01439555
View directory record Official record
Conditions
Alzheimer's Disease
Interventions
Simvastatin, L-Arginine, Tetrahydrobiopterin
Drug
Lead sponsor
University of Massachusetts, Worcester
Other
Eligibility
55 Years to 85 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Worcester, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Jul 22, 2026, 3:18 AM EDT
Withdrawn No phase listed Observational

Determining the Association of Microvascular Disease as Assessed by PET and Graft Injury by Donor Derived Cell Free DNA

NCT05756088
View directory record Official record
Conditions
Cardiac Allograft Vasculopathy, Endothelial Dysfunction, Microvascular Coronary Artery Disease
Interventions
Blood draw to measure the levels of dd-cf DNA
Diagnostic Test
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Nov 5, 2025 · Synced Jul 22, 2026, 3:18 AM EDT
Completed Phase 2 Interventional

Antioxidant Functions of Lipoic Acid

NCT00065624
View directory record Official record
Conditions
Hypercholesterolemia
Interventions
lipoic acid
Drug
Lead sponsor
National Center for Complementary and Integrative Health (NCCIH)
NIH
Eligibility
50 Years to 75 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2007
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 1, 2007 · Synced Jul 22, 2026, 3:18 AM EDT
Completed Phase 2 Interventional Results available

Pilot Study About the Harmful Effects of Blood Storage on Overweight People and the Role of iNO in This Setting

NCT01529502
View directory record Official record
Conditions
Blood Transfusion, Endothelial Physiopathology, Nitric Oxide, Pulmonary Hypertension
Interventions
Red blood Cells auto-transfusion, Inhaled Nitric Oxide (iNO) administration
Procedure · Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 60 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated May 21, 2017 · Synced Jul 22, 2026, 3:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Vascular Endothelial Inflammation and Dysfunction in Pediatric Long-term Cancer Survivors

NCT02032121
View directory record Official record
Conditions
Cancer Survivor, Pediatric Cancer
Interventions
Blood specimen, Echocardiography
Procedure
Lead sponsor
University of Miami
Other
Eligibility
6 Years to 30 Years
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2015
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 8, 2015 · Synced Jul 22, 2026, 3:18 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Exosome Cargo From Preeclampsia Patients

NCT04154332
View directory record Official record
Conditions
Preeclampsia
Interventions
Sample collection
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2031
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Jul 6, 2026 · Synced Jul 22, 2026, 3:18 AM EDT
Recruiting Phase 3 Interventional

AURN001 Efficacy in Participants With Corneal Edema Secondary to Corneal Endothelial Dysfunction

NCT07368959
View directory record Official record
Conditions
Corneal Edema, Corneal Endothelial Dysfunction, Fuchs Endothelial Corneal Dysfunction, Pseudophakic Bullous Keratopathy (PBK)
Interventions
Combination Product: AURN001 + Y-27632, Placebo
Drug · Other
Lead sponsor
Aurion Biotech
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
12
States / cities
Mesa, Arizona • Little Rock, Arkansas • Fort Collins, Colorado + 9 more
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Jul 22, 2026, 3:18 AM EDT
Withdrawn Phase 2 Interventional

Effect of an Inhaled Glucocorticoid-long-acting Beta Adrenergic Agonist on Endothelial Function in COPD

NCT01209715
View directory record Official record
Conditions
COPD
Interventions
Placebo, Fluticasone /salmeterol
Drug
Lead sponsor
University of Miami
Other
Eligibility
18 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Jul 22, 2026, 3:18 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Vascular Effects of High-Salt After Preeclampsia

NCT06749418
View directory record Official record
Conditions
Preeclampsia, Preeclampsia Postpartum
Interventions
Eplerenone
Drug
Lead sponsor
Anna Stanhewicz, PhD
Other
Eligibility
18 Years to 45 Years · Female only
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Feb 12, 2026 · Synced Jul 22, 2026, 3:18 AM EDT
Recruiting Early Phase 1 Interventional Accepts healthy volunteers

Oxidative Stress in Microvascular Dysfunction Following Gestational Diabetes

NCT05946785
View directory record Official record
Conditions
Gestational Diabetes, Vascular Endothelial Function
Interventions
Acetylcholine, insulin aspart
Drug
Lead sponsor
Anna Stanhewicz, PhD
Other
Eligibility
18 Years to 50 Years · Female only
Enrollment
28 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2027
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 12, 2025 · Synced Jul 22, 2026, 3:18 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Effect of EGCG on the Body's Response to Insulin

NCT00434499
View directory record Official record
Conditions
Hypertension, Obesity, Type 2 Diabetes, Insulin Resistance
Interventions
EGCG
Drug
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
21 Years to 65 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2015
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 3, 2022 · Synced Jul 22, 2026, 3:18 AM EDT
Completed Not applicable Interventional

Aldosterone and Vascular Disease in Diabetes Mellitus

NCT00214825
View directory record Official record
Conditions
Diabetes Mellitus, Endothelial Dysfunction, Albuminuria
Interventions
eplerenone, Hydrochlorothiazide
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
21 Years to 64 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 2, 2008 · Synced Jul 22, 2026, 3:18 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Flavonoids in the Treatment of Endothelial Dysfunction in Children With Diabetes

NCT01307917
View directory record Official record
Conditions
Diabetic Nephropathy, Endothelial Dysfunction
Interventions
flavonoids
Dietary Supplement
Lead sponsor
Texas Tech University Health Sciences Center
Other
Eligibility
12 Years to 21 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2012
U.S. locations
1
States / cities
Amarillo, Texas
Source: ClinicalTrials.gov public record
Updated Dec 16, 2012 · Synced Jul 22, 2026, 3:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

FFA-Induced Hypertension and Endothelial Dysfunction

NCT00589888
View directory record Official record
Conditions
Endothelial Dysfunction, Hypertension
Interventions
Intralipid 20% @ 20cc/hour, Intralipid 20%@ 40cc/hour, Normal Saline, 32-gram oral fat load, 64-gram oral fat load
Drug · Dietary Supplement
Lead sponsor
Emory University
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2006 – 2008
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Oct 15, 2018 · Synced Jul 22, 2026, 3:18 AM EDT
Active, not recruiting No phase listed Observational

A Study to Evaluate Homocysteine Metabolism and Endothelial Function in ADPKD

NCT05193981
View directory record Official record
Conditions
Autosomal Dominant Polycystic Kidney Disease
Interventions
Not listed
Lead sponsor
Mayo Clinic
Other
Eligibility
15 Years to 40 Years
Enrollment
80 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Apr 15, 2026 · Synced Jul 22, 2026, 3:18 AM EDT
Completed Phase 3 Interventional Results available

Mineralocorticoid Antagonism and Endothelial Dysfunction in Autosomal Dominant Polycystic Kidney Disease (ADPKD)

NCT01853553
View directory record Official record
Conditions
ADPKD
Interventions
Spironolactone, Sugar pill
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
20 Years to 55 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2017
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 19, 2019 · Synced Jul 22, 2026, 3:18 AM EDT
Completed Not applicable Interventional

Urolithin A Supplementation in Middle-aged Adults With Obesity

NCT05921266
View directory record Official record
Conditions
Obesity, Vascular Dementia, Cognitive Impairment
Interventions
Urolithin A, Placebo
Dietary Supplement · Other
Lead sponsor
University of Oklahoma
Other
Eligibility
40 Years to 64 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Jun 25, 2025 · Synced Jul 22, 2026, 3:18 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Creatine Monohydrate Supplementation and Vascular Endothelial Health

NCT05014659
View directory record Official record
Conditions
Endothelial Dysfunction, Oxidative Stress
Interventions
Creatine monohydrate, Placebo
Dietary Supplement
Lead sponsor
Florida State University
Other
Eligibility
50 Years to 64 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2022
U.S. locations
1
States / cities
Tallahassee, Florida
Source: ClinicalTrials.gov public record
Updated Jan 12, 2023 · Synced Jul 22, 2026, 3:18 AM EDT
Terminated Phase 3 Interventional Accepts healthy volunteers Results available

Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3

NCT00878969
View directory record Official record
Conditions
Oxidative Stress, Endothelial Dysfunction
Interventions
valsartan (ARB), ramipril (ACE inhibitor), Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2015
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 14, 2016 · Synced Jul 22, 2026, 3:18 AM EDT